In the context of postpartum hemorrhage, the WOMAN trial (2017) tested which intervention and found what primary outcome benefit?

• A Recombinant Factor VIIa; reduced need for surgical intervention
• B Fresh frozen plasma; reduced total blood transfused
• C Tranexamic acid; reduced death from PPH bleeding ✓
• D Carboprost; reduced hysterectomy rate

Explanation

The WOMAN trial (World Maternal Antifibrinolytic trial, 2017) was a large randomised trial in which tranexamic acid (1 g IV, repeated if necessary within 24 hours) was given to women with clinically diagnosed PPH after vaginal or caesarean birth. It demonstrated a significant reduction in death due to bleeding (primary outcome) without increasing adverse events. It did not show benefit if given after 3 hours of delivery.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.